Get the Stockscreener App
2.04
13.97%
0.25
Alx Oncology Holdings Inc stock is traded at $2.04, with a volume of 14.46M.
It is up +13.97% in the last 24 hours and up +5.70% over the past month.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
See More
Previous Close:
$1.79
Open:
$1.79
24h Volume:
14.46M
Relative Volume:
10.86
Market Cap:
$274.51M
Revenue:
-
Net Income/Loss:
$-101.70M
P/E Ratio:
-1.0759
EPS:
-1.8961
Net Cash Flow:
$-84.35M
1W Performance:
+33.33%
1M Performance:
+5.70%
6M Performance:
+53.38%
1Y Performance:
+350.73%
1-Day Range:
$1.765
$2.13
1-Week Range:
$1.54
$2.13
52-Week Range:
$0.404
$2.66
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Name
Alx Oncology Holdings Inc
Sector
Industry
Phone
650-466-7125
Address
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare ALXO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
2.04 | 274.51M | 0 | -101.70M | -84.35M | -1.8961 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-19-26 | Initiated | Wells Fargo | Overweight |
| Mar-06-26 | Resumed | UBS | Buy |
| Nov-13-25 | Initiated | Jefferies | Buy |
| Mar-06-25 | Upgrade | Jefferies | Hold → Buy |
| Dec-19-24 | Downgrade | Jefferies | Buy → Hold |
| Mar-08-24 | Downgrade | Stifel | Buy → Hold |
| Dec-08-23 | Upgrade | Jefferies | Hold → Buy |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-21 | Initiated | Stifel | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-06-21 | Initiated | UBS | Buy |
| Feb-10-21 | Initiated | H.C. Wainwright | Buy |
| Aug-11-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-11-20 | Initiated | Credit Suisse | Outperform |
| Aug-11-20 | Initiated | Jefferies | Buy |
| Aug-11-20 | Initiated | Piper Sandler | Overweight |
View All
Alx Oncology Holdings Inc Stock (ALXO) Latest News
Alx Oncology HoldingsEnters Loan And Security Agreement With HSBC Ventures On June 25, 2026SEC Filing - TradingView
ALX Oncology Secures New $50 Million Loan Facility - TipRanks
ALX Oncology (NASDAQ: ALXO) adds up to $50M secured loan facility - Stock Titan
ALX Oncology Holdings, Inc. Actuals & Estimates (NASDAQ:ALXO) - TradingView
ALXO Forecast — Price Target — Prediction for 2027 - TradingView
ALX Oncology Holdings Inc (ALXO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ALX Oncology: Rebuilding From Critical Setbacks (NASDAQ:ALXO) - Seeking Alpha
ALX Oncology Holdings Inc (ALXO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ALXO News | ALX ONCOLOGY HOLDINGS INC (NASDAQ:ALXO) - ChartMill
ALX Oncology Holdings Inc (ALXO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ALX Oncology Holdings Inc (ALXO) Valuation: PE, PB & Fair Value Analysis - TradingKey
ALX Oncology Holdings Inc (ALXO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ALX Oncology Holdings Inc (ALXO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ALX Oncology Holdings Inc (ALXO) Institutional Confidence - TradingKey
ALX Oncology Holdings Inc (ALXO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ALX Oncology Holdings Inc (ALXO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ALXO Q1 2026 Earnings: EPS Beat Amid Pre‑Revenue Development StageMargin Guidance - newsline.com
ALX Oncology (ALXO) Edges Higher: Near-Term Support and Resistance in FocusLow Volume Node - newsline.com
ALXO Q1 2026 Earnings: EPS Surprise of 26.23% Highlights Cost Discipline Amid Clinical ProgressRevenue Recognition Risk - newsline.com
ALXO Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Shares HigherEarnings Cycle Outlook - newsline.com
ALX Oncology Shareholders Approve Directors and Executive Pay - TipRanks
ALX Oncology (NASDAQ: ALXO) holders back board slate, executive pay and KPMG audit - Stock Titan
ALX Oncology targets key readouts to advance CD47, EGFR cancer drug programs - MSN
ALXO: All voting proposals passed and clinical programs advanced, with key data expected soon - TradingView
ALX Oncology Holdings Inc Annual Shareholders Meeting Transcript - GuruFocus
ALXO Q1 2026 Earnings: EPS Beat Highlights Improved Cost Control in Pre-Revenue StageManagement Tone Analysis - newsline.com
ALXO Q1 2026 Earnings: Narrower-Than-Expected Loss Reflects Disciplined Cost ManagementFinancial Health Score - newsline.com
ALX Oncology (ALXO) Q1 2026 Earnings Transcript - AOL.com
ALXO Q1 2026 Earnings: EPS Beat Driven by Lower Expenses, Stock Slightly DownProfit Cycle Analysis - newsline.com
Insider Returns Down To US$122k As ALX Oncology Holdings' Stock Dips 15% - simplywall.st
ALX Oncology Targets Key Readouts to Advance CD47, EGFR Cancer Drug Programs - inkl
ALXO: Evorpacept and ALX2004 advance with strong data, robust funding, and pivotal trials planned - TradingView
ALXO: Evorpacept and ALX2004 advance with strong data, targeting high unmet needs and pivotal trials ahead - TradingView
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data - The Globe and Mail
ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York - Investing News Network
Cancer-therapy biotech ALX Oncology to join Jefferies 2026 - Stock Titan
ALXO Stock Chart | ALX ONCOLOGY HOLDINGS INC (NASDAQ:ALXO) - ChartMill
ALX Oncology Slips 1.5% as Biotech Stock Tests Key Support at $1.83Fibonacci Entry Signals - newsline.com
ALXO Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Progress in Evorpacept DevelopmentEPS Revision Trend - The Legal Advocate
ALX Oncology Holdings (ALXO) Holds Steady Near Support as Biotech Sector Watches Catalyst CalendarTrend Reversal Picks - newsline.com
Is ALX Oncology Holdings (ALXO) outperforming other medical stocks this year? - MSN
ALX Oncology (ALXO) Edges Higher Amid Modest Buying Interest; Resistance at $2.06 in FocusMoney Flow Index - The Legal Advocate
ALX Oncology (ALXO) Lightstone group falls below 5% ownership - Stock Titan
ALXO Q1 2026 Earnings: Narrower-than-Expected Loss per Share Mirrors Clinical-Stage FocusEarnings Season Outlook - newsline.com
ALXO Q1 2026 Earnings: EPS Beat Highlights Controlled Cash Burn, No Revenue YetDividend Cut Risk - Newser
Why Is ALX Oncology Holdings Inc. (ALXO) Stock Down Today? - Meyka
ALXO Stock Price, Quote & Chart | ALX ONCOLOGY HOLDINGS INC (NASDAQ:ALXO) - ChartMill
Redmile Group, ALXO: Investment manager discloses 6.8% ownership - Stock Titan
HBM Healthcare (ALXO) discloses 8.59M shares, ~6.5% stake - Stock Titan
Alx Oncology Holdings Inc Stock (ALXO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):